Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

Abstract:

BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the extent of liver fibrosis yet there is little evidence quantifying the cost effectiveness of RGT particularly conditional upon fibrosis stage. OBJECTIVE:This study describes an economic model designed to assess the costs and benefits of RGT compared with standard duration of therapy (SDT) in hepatitis C virus genotype 1 patients. METHODS:A Markov cohort simulation model with lifetime perspective was developed to undertake a cost utility analysis of RGT in the UK. Patients entered the model at Metavir disease stages F0-F4, and progressed through these stages via age and duration of HCV infection-dependent transition probabilities. Treated patients were partitioned according to virological response and shortened or extended duration of therapy was applied following European guidelines. RESULTS:For all patients, SDT and RGT was associated with an increase of 2.14 and 2.20 QALYs and £2,374 and £2,270 costs, respectively, compared with no treatment. Overall, RGT was a dominant scenario being associated with a lower risk of complications, increased QALYs (0.08) and cost saving (£101). RGT across fibrosis stages was either highly cost effective or dominant; in all cases RGT was associated with an increase in QALYs, driven by a reduction in complications in DVR subjects and reduced exposure to treatment disutility in RVR subjects; costs were lower in F1 and F2 fibrosis stages. At a willingness-to-pay threshold of £20,000 per QALY, overall RGT across fibrosis stages F2-F4 were associated with the highest probability of being cost effective. At this threshold, the probability of reduced/extended therapy in RVR/DVR patients being cost effective is 0.35 and 0.88, respectively. CONCLUSIONS:This analysis suggests that the treatment of HCV genotype 1 patients in fibrosis stage F2 has the greatest potential for maximizing health benefit and cost saving within an RGT protocol. Predicting those patients most likely to respond to treatments is important from both a clinical and cost perspective and the tailoring of treatment duration with the current standard of care is likely to remain a priority for payers with budgetary constraints.

authors

McEwan P,Kim R,Yuan Y

doi

10.1007/s40258-012-0002-0

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

53-63

issue

1

eissn

1175-5652

issn

1179-1896

journal_volume

11

pub_type

杂志文章
  • Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance.

    abstract::The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-018-0447-x

    authors: Dale M,Morgan H,Carter K,White J,Carolan-Rees G

    更新日期:2019-02-01 00:00:00

  • A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

    abstract:BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-015-0183-4

    authors: Campbell JR,Sasitharan T,Marra F

    更新日期:2015-08-01 00:00:00

  • Household Size and the Decision to Purchase Health Insurance in Cambodia: Results of a Discrete-Choice Experiment with Scale Adjustment.

    abstract:BACKGROUND:Community-based health insurance (CBHI) schemes have been introduced in low- and middle-income countries to increase health service utilization and provide financial protection from high healthcare expenditures. OBJECTIVE:We assess the impact of household size on decisions to enroll in CBHI and demonstrate ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0222-9

    authors: Ozawa S,Grewal S,Bridges JF

    更新日期:2016-04-01 00:00:00

  • Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.

    abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0180-7

    authors: Shields GE,Bates AE,Chapman AM

    更新日期:2015-10-01 00:00:00

  • Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease.

    abstract:OBJECTIVES:To analyse the cost effectiveness of community-based case management for patients suffering from chronic obstructive pulmonary disease (COPD). METHODS:The study took place in the third largest municipality in Denmark and was conducted as a randomised controlled trial with 12 months of follow-up. A total of ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0298-2

    authors: Sørensen SS,Pedersen KM,Weinreich UM,Ehlers L

    更新日期:2017-06-01 00:00:00

  • Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.

    abstract:OBJECTIVE:Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of foreign countries. Our objective is to quantify the theoretical cross-border spill-over effects of cross-reference pricing schemes on pharmaceutical prices in the former EU-15 countries. METHODS:An ana...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200605040-00005

    authors: Stargardt T,Schreyögg J

    更新日期:2006-01-01 00:00:00

  • Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

    abstract:BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients wit...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0272-z

    authors: Kostić M,Djakovic L,Šujić R,Godman B,Janković SM

    更新日期:2017-02-01 00:00:00

  • Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.

    abstract:BACKGROUND:When pharmaceuticals are administered based on patient characteristics (for example weight or body surface area), an amount of product will be unused and must be disposed of. This wastage represents inefficiency and can distort decision making. METHODS:We present a method for the analysis of optimum fill vo...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0444-0

    authors: Hatswell AJ,Porter JK

    更新日期:2019-06-01 00:00:00

  • Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

    abstract:BACKGROUND:Patients with venous thromboembolism (VTE) commonly have an underlying genetic predisposition. However, genetic tests nowadays in use have very low sensitivity for identifying subjects at risk of VTE. Thrombo inCode(®) is a new genetic tool that has demonstrated very good sensitivity, thanks to very good cov...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0153-x

    authors: Rubio-Terrés C,Soria JM,Morange PE,Souto JC,Suchon P,Mateo J,Saut N,Rubio-Rodríguez D,Sala J,Gracia A,Pich S,Salas E

    更新日期:2015-04-01 00:00:00

  • Inclusion of compliance and persistence in economic models: past, present and future.

    abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03261872

    authors: Kadambi A,Leipold RJ,Kansal AR,Sorensen S,Getsios D

    更新日期:2012-11-01 00:00:00

  • How a Bottom-Up Multi-Stakeholder Initiative Helped Transform the Renal Replacement Therapy Landscape in Spain.

    abstract::Healthcare reforms aim to change certain parts of the health system to improve quality of care, access, or financial sustainability. Traditionally, healthcare reform is understood as an action undertaken by a government at a national or local level. However, bottom-up changes can also lead to improvements in the healt...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-017-0315-0

    authors: Selgas R,Rodriguez L,Julian JC,Remon C,Prieto-Velasco M,Perez-Contreras J,Fontan MP,GADDPE.

    更新日期:2017-12-01 00:00:00

  • Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

    abstract:BACKGROUND:Liposomal amphotericin B (L-AMB) and amphotericin B lipid complex (ABLC) are both indicated for treating invasive fungal infections (IFIs) caused by Aspergillus, Candida and Cryptococcus spp. among patients who are refractory to or intolerant of conventional amphotericin B (CAB). Prior studies have suggested...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0072-7

    authors: Yang H,Chaudhari P,Zhou ZY,Wu EQ,Patel C,Horn DL

    更新日期:2014-02-01 00:00:00

  • Explaining the health costs associated with managing intracranial aneurysms in Italy.

    abstract:BACKGROUND:The clinical management of intracranial aneurysms is debated in many countries because of the associated disability risk and costs. Therefore, estimating the costs and explaining their variability will provide important information for decision makers. OBJECTIVE:We aimed to evaluate the acute and post-acute...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0041-1

    authors: Calciolari S,Torbica A,Tarricone R

    更新日期:2013-08-01 00:00:00

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256162

    authors: Sermet C,Andrieu V,Godman B,Van Ganse E,Haycox A,Reynier JP

    更新日期:2010-01-01 00:00:00

  • Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.

    abstract::One focus of health economics is the trade-off between limited resources and the (health) needs of a community. Cost-effectiveness analysis (CEA), while being one of the most accepted evaluation methodologies in health economics, does not account for many important costs and benefits of health care interventions. Some...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Bridges JF

    更新日期:2003-01-01 00:00:00

  • Prescribing incentive schemes : a useful approach?

    abstract:INTRODUCTION:From 2000 to 2004, primary care organisations (PCOs) in England were legally required to operate a prescribing incentive scheme for their general practices. A statutory framework specified the types of target, maximum rewards and use of 'good cause for failure' provisions that schemes should include. Our o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200504020-00005

    authors: Mason AR,Drummond MF,Hunter JA,Towse AK,Cooke J

    更新日期:2005-01-01 00:00:00

  • Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.

    abstract:BACKGROUND:Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. OBJECTIVE:To estimate the cost effectivene...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11535520-000000000-00000

    authors: Logman JF,Heeg BM,Herlitz J,van Hout BA

    更新日期:2010-01-01 00:00:00

  • A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges?

    abstract:BACKGROUND AND OBJECTIVES:Generic substitution has been introduced in most countries in order to reduce costs and improve access to drugs. However, regulations and the generic drugs available vary between countries. It is the prescriber or dispenser of the drug who is the final decision maker. Nevertheless, physicians'...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-014-0145-2

    authors: Toverud EL,Hartmann K,Håkonsen H

    更新日期:2015-08-01 00:00:00

  • Cost data assessment in multinational economic evaluations: some theory and review of published studies.

    abstract::This article reviews the concept of costing, and how cost data have been considered and reported in recent multinational economic evaluations. It appears that current practice frequently does not comply with microeconomic foundations and standards for good practice. A number of studies fail to indicate the year of cos...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Halliday RG,Darba J

    更新日期:2003-01-01 00:00:00

  • The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.

    abstract:BACKGROUND AND OBJECTIVE:Opinions on the use of research abstracts in policy decision making are conflicting. We sought to evaluate the influence of research abstracts in guiding decisions of the Joint Oncology Drug Review of Canada (JODR), which conducts clinical and economic reviews of new cancer treatment drugs for ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11530510-000000000-00000

    authors: Weizman AV,Griesman J,Bell CM

    更新日期:2010-01-01 00:00:00

  • Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?

    abstract::The mandatory nature of recommendations made by the National Institute for Health and Clinical Excellence (NICE) in the UK has highlighted inherent difficulties in the process of disinvestment in existing technologies to fund NICE-approved technologies. A lack of evidence on candidate technologies means that the proce...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256137

    authors: Karnon J,Carlton J,Czoski-Murray C,Smith K

    更新日期:2009-01-01 00:00:00

  • Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for Low Back Pain: a Systematic Literature Review.

    abstract:BACKGROUND:Low back pain (LBP) is a major health problem, having a substantial effect on peoples' quality of life and placing a significant economic burden on healthcare systems and, more broadly, societies. Many interventions to alleviate LBP are available but their cost effectiveness is unclear. OBJECTIVES:To identi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0268-8

    authors: Andronis L,Kinghorn P,Qiao S,Whitehurst DG,Durrell S,McLeod H

    更新日期:2017-04-01 00:00:00

  • Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada.

    abstract:BACKGROUND:Although suicide-prevention campaigns have been implemented in numerous countries, Canada has yet to implement a strategy nationally. This is the first study to examine the cost utility of the implementation of a multidimensional suicide-prevention program that combines several interventions over a 50-year t...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00511-5

    authors: Lebenbaum M,Cheng J,de Oliveira C,Kurdyak P,Zaheer J,Hancock-Howard R,Coyte PC

    更新日期:2020-04-01 00:00:00

  • Healthcare payment incentives: a comparative analysis of reforms in Taiwan, South Korea and China.

    abstract::Payment incentives to both consumers and providers have significant consequences for the equity and efficiency of a healthcare system, and have recently come to the fore in health policy reforms. This review first discusses the economic rationale for the apparent international convergence toward payment systems with m...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403010-00009

    authors: Eggleston K,Hsieh CR

    更新日期:2004-01-01 00:00:00

  • Reducing smoking prevalence in Australian prisons: a review of policy options.

    abstract::Smoking of tobacco products is a major public health challenge in prison settings in most countries. Although tobacco use was tolerated by custodial authorities for many decades, the overwhelming evidence of the adverse public health effects of tobacco on both the smokers and those in the vicinity of exhaled or passiv...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Awofeso N

    更新日期:2002-01-01 00:00:00

  • Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

    abstract:BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11592220-000000000-00000

    authors: Gazzard B,Hill A,Anceau A

    更新日期:2011-07-01 00:00:00

  • Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.

    abstract:BACKGROUND:South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea. METHODS:We pull...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00547-7

    authors: Lee HJ,Han E,Kim H

    更新日期:2020-08-01 00:00:00

  • Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis.

    abstract:BACKGROUND:The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0397-3

    authors: Pallas SW,Courey M,Hy C,Killam WP,Warren D,Moore B

    更新日期:2018-08-01 00:00:00

  • Demand for outpatient healthcare: empirical findings from rural India.

    abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256160

    authors: Sarma S

    更新日期:2009-01-01 00:00:00

  • Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

    abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00496-1

    authors: Vreman RA,Geenen JW,Hövels AM,Goettsch WG,Leufkens HGM,Al MJ

    更新日期:2019-12-01 00:00:00